Sorted By Test Name - Mayo Medical Laboratories

FPCPD
83358
PLHBB
9096
Plasma Cell Proliferative Disorder (PCPD), FISH
Clinical Information: Multiple myeloma is a hematologic neoplasm that generally originates in the
bone marrow and develops from malignant plasma cells. There are 4 main categories of plasma cell
proliferative disorders (PCPDs): asymptomatic myeloma, smoldering myeloma, indolent myeloma, and
multiple myeloma. Asymptomatic myeloma patients have nonspecific symptoms that may be attributed to
other diseases. Generalized bone pain, anemia, numbness or limb weakness, symptoms of hypercalcemia,
and recurrent infections are all symptoms that may indicate myeloma. In smoldering myeloma there is a
monoclonal protein spike, but it is stable. Indolent myeloma is a slowly progressing myeloma. As
myeloma progresses, the malignant plasma cells interfere with normal blood product formation in the
bone marrow resulting in anemia and leukopenia. Myeloma also causes an overstimulation of osteoclasts,
causing excessive breakdown of bone tissue without the normal corresponding bone formation. These
bone lesions are seen in approximately 66% of myeloma patients. In advanced disease, bone loss may
reach a degree where the patient suffers fractures easily.
Useful For: Aiding in the diagnosis of new cases of multiple myeloma or other plasma cell
proliferative disorders Identifying prognostic markers based on the anomalies found
Interpretation: A neoplastic clone is detected when the percent of cells with an abnormality exceeds
the normal reference range for any given probe.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Fonseca R, Blood E, Rue M, et al: Clinical and biologic implications of
recurrent genomic aberrations in myeloma. Blood 2003 Jun 1;101(11):4569-4575 2. Fonseca R, Blood
EA, Oken MM, et al: Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique
subset of patients. Blood 2002 May 15;99(10):3735-3741 3. Shaughnessy J, Tian E, Sawyer J, et al: High
incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.
Blood 2000 Aug 15;96(4):1505-1511
Plasma Hemoglobin, Plasma
Clinical Information: Plasma normally contains no free hemoglobin ie, no hemoglobin that is not
contained in erythrocytes. Significant amounts of hemoglobin occur in plasma following hemolysis such
as might result from a transfusion reaction or mechanical fragmentation of red blood cells during cardiac
surgery.
Useful For: Determining whether hemolysis is occurring such as from: -Transfusion reaction
-Mechanical fragmentation of red blood cells
Interpretation: Total hemoglobin: > or =12 months: 0.0-15.2 mg/dL Reference values have not been
established for patients who are less than 12 months of age. Oxyhemoglobin: > or =12 months: 0.0-12.4
mg/dL Reference values have not been established for patients who are less than 12 months of age.
Reference Values:
TOTAL HEMOGLOBIN
> or =12 months: 0.0-15.2 mg/dL
Reference values have not been established for patients who are less than 12 months of age.
OXYHEMOGLOBIN
> or =12 months: 0.0-12.4 mg/dL
Reference values have not been established for patients who are less than 12 months of age.
Clinical References: Fairbanks VF, Ziesmer SC, O'Brien PC: Methods for measuring plasma
hemoglobin in micromolar concentration compared. Clin Chem 1992;38:132-140
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1428